K

Knight Therapeutics Inc
TSX:GUD

Watchlist Manager
Knight Therapeutics Inc
TSX:GUD
Watchlist
Price: 5.29 CAD -0.19% Market Closed
Market Cap: 534.2m CAD
Have any thoughts about
Knight Therapeutics Inc?
Write Note

Wall Street
Price Targets

GUD Price Targets Summary
Knight Therapeutics Inc

Wall Street analysts forecast GUD stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GUD is 6.9 CAD with a low forecast of 6.16 CAD and a high forecast of 7.88 CAD.

Lowest
Price Target
6.16 CAD
16% Upside
Average
Price Target
6.9 CAD
30% Upside
Highest
Price Target
7.88 CAD
49% Upside
Knight Therapeutics Inc Competitors:
Price Targets
000423
Dong-E-E-Jiao Co Ltd
35% Upside
CIPLA
Cipla Ltd
12% Upside
AJANTPHARM
Ajanta Pharma Ltd
2% Upside
002294
Shenzhen Salubris Pharmaceuticals Co Ltd
3% Upside
600993
Mayinglong Pharmaceutical Group Co Ltd
53% Upside
600085
Beijing Tongrentang Co Ltd
28% Upside
4516
Nippon Shinyaku Co Ltd
5% Downside

Revenue
Forecast

Revenue Estimate
Knight Therapeutics Inc

For the last 8 years the compound annual growth rate for Knight Therapeutics Inc's revenue is 106%. The projected CAGR for the next 3 years is 9%.

106%
Past Growth
9%
Estimated Growth
Estimates Accuracy
3%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Knight Therapeutics Inc

The compound annual growth rate of Knight Therapeutics Inc's operating income for the next 2 years is 135%.

N/A
Past Growth
135%
Estimated Growth
Estimates Accuracy
N/A
Average

Net Income
Forecast

Net Income Estimate
Knight Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
33%
Average Beat

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is GUD's stock price target?
Price Target
6.9 CAD

According to Wall Street analysts, the average 1-year price target for GUD is 6.9 CAD with a low forecast of 6.16 CAD and a high forecast of 7.88 CAD.

What is Knight Therapeutics Inc's Revenue forecast?
Projected CAGR
9%

For the last 8 years the compound annual growth rate for Knight Therapeutics Inc's revenue is 106%. The projected CAGR for the next 3 years is 9%.

What is Knight Therapeutics Inc's Operating Income forecast?
Projected CAGR
135%

The compound annual growth rate of Knight Therapeutics Inc's operating income for the next 2 years is 135%.

Back to Top